<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
 

Crown Bioscience US: Two Centers of Excellence. One Connected Research Network.

November 19, 2026
Crown Bioscience US: Two Centers of Excellence. One Connected Research Network.
6:12
SHARE

As pharmaceutical and biotechnology companies increasingly evaluate where they conduct preclinical and translational research, access to strong US-based CRO capabilities is becoming an important factor in partner selection.

Crown Bioscience's survey of more than 100 therapeutic companies found that 38% of respondents said legislation such as the BIOSECURE Act had affected their CRO selection, while 41% said geopolitical tensions had changed how they evaluate CRO partners. With the BIOSECURE Act and Executive Order 14117 adding further considerations around biotechnology suppliers, data security, and sample analysis, access to US-based research capabilities is increasingly important.

Crown Bioscience US brings together our North Carolina and San Diego facilities as one connected research network. Each site contributes specialized expertise, but their combined capabilities offer clients access to extensive oncology models, complementary research platforms, and integrated preclinical and clinical biomarker services across the United States.

Two Centers of Excellence, Working as One

North Carolina brings extensive PDX expertise, supported by a biobank of thousands of Asian and Western PDX models. Its capabilities in model revival, warm passage, expansion, and in vivo efficacy studies support rapid study initiation and operational flexibility.

San Diego complements this with extensive CDX and PDX collections, in vivo and in vitro research, specialized surgical approaches, orthotopic models, and advanced translational biomarker capabilities.

Importantly, these capabilities are not isolated by location. The teams work within the same US network, connecting study execution and analytical expertise to support individual program requirements.

Across Crown Bioscience US, clients have access to:

  • Oncology models: Extensive PDX and CDX collections, including rare, pretreated, and treatment-resistant tumor models.
  • Preclinical research: In vivo and in vitro studies, PDX efficacy research, orthotopic implantation, specialized surgical approaches, and matched organoid-PDX models.
  • Advanced platforms: High-throughput and high-content imaging, specialized neuroscience expertise, and complex oncology study designs, including brain tumor research.
  • Biomarker services: Flow cytometry, pathology, histology, cytokine detection, genomics, NGS, and multi-omics profiling.

This combined offering allows clients to leverage North Carolina's PDX resources alongside San Diego's broader research and analytical capabilities, with study strategies shaped around scientific needs rather than the limitations of a single facility.

Crown Bioscience offers customers a more connected and efficient approach to preclinical research. Rather than coordinating multiple vendors, customers can seamlessly move between model development, in vitro screening, in vivo studies, and molecular characterization within a single integrated partner.

This approach reduces the complexity of managing multiple providers, improves continuity across studies, and enables findings from one stage to inform the next. With access to a broader range of expertise and capabilities, customers can streamline study planning, accelerate decision-making, and advance their programs with greater confidence.

Connecting Preclinical Research with Clinical Biomarkers

One key strength is the ability to connect preclinical study capabilities with downstream biomarker analysis.

Across our US network, clients can access preclinical biomarker platforms alongside clinical testing capabilities, including:

  • CAP/CLIA accredited laboratories.
  • Fit-for-purpose assay development for research use only (RUO) applications and clinical trials.
  • Board-certified pathologist evaluation.
  • Flow cytometry, pathology, histology, and cytokine analysis.
  • Genomics and advanced biomarker profiling.

This connectivity is particularly relevant as data security and regulatory requirements evolve. In connection with Executive Order 14117 and its associated data-security requirements, US personnel-derived PDX models (with some exceptions for models retained in China) and US clinical samples can currently only be analyzed in the US.

The Value of One Connected US Partner

Choosing a CRO involves more than scientific capabilities. Communication, regulatory knowledge, project management, data quality, and study timelines all influence research progression.

Crown Bioscience US brings these considerations together through:

  • US-based operations: Two centers of excellence providing access to complementary research and laboratory capabilities.
  • Responsive collaboration: Same-time-zone communication and direct access to scientific and project management teams.
  • Simplified logistics: US-based study execution and sample analysis to help reduce international shipping and processing complexities.
  • Scientific flexibility: Access to complementary models, platforms, and expertise across both facilities.
  • Consistent quality: Established workflows, experienced scientific teams, and a focus on reproducible data.

Coast to coast centers of excellence partner together to provide highest quality study execution. US partnerships ease logistical barriers with onshore warm Western and Asian PDX models that accelerate study timelines.

For 20 years, our pursuit has been the development of answers that expand what's possible.
Our focus is to we tailor every program against your specific need for:

  • Speed, to act when it matters.
  • Efficiency to maximize opportunity within your constraints.
  • Flexibility, to evolve your program as new insights emerge.

And now, to complete our operational offer we have expanded our global network to include new and enhanced capabilities across the United States, giving you better access to our expertise, our platforms, your samples and your data - in the timeframe and location you need them to be. Contact us to see what Crown Bioscience US can do for your studies.

 

Frequently Asked Questions

What capabilities are available through Crown Bioscience's US sites?

Crown Bioscience's San Diego and North Carolina sites offer complementary preclinical research capabilities, including cell-based screening, organoid models, PDX and CDX studies, humanized models, molecular characterization, and biomarker analysis. Together, these services support programs from early discovery through preclinical development. 

What are the benefits of conducting an integrated study across both US sites?

Working with a single partner across multiple research stages reduces vendor coordination, simplifies study management, and improves continuity between experiments. By connecting in vitro, in vivo, and analytical capabilities, customers can generate more comprehensive data, streamline decision-making, and reduce delays associated with transferring studies between providers. 

Can I start with one service and expand my study as my program progresses?

Yes. Customers can engage Crown Bioscience for a standalone service or build an integrated research program. For example, a project may begin with cell panel screening, progress to organoid testing, and advance to PDX efficacy studies and biomarker analysis as additional data and validation are needed. 

How do the San Diego and North Carolina sites work together?

The two sites bring together complementary scientific expertise and research capabilities. North Carolina's PDX-focused capabilities can support model development and in vivo studies, while San Diego provides additional screening, translational research, and analytical services. This coordinated approach allows customers to access specialized capabilities through one research partner. 

What are the advantages of conducting preclinical research entirely within the US?

US-based research can help customers address geographic, regulatory, and data-handling requirements, particularly for patient-derived models, human biospecimens, and sensitive genomic information. Crown's US capabilities can support customers seeking to minimize cross-border sample transfers, simplify compliance considerations, and maintain greater oversight of their research programs. 

 

Cite this Article

Baillargeon, M., (2026) Crown Bioscience US: Two Centers of Excellence. One Connected Research Network. - Crown Bioscience. https://blog.crownbio.com/crown-bioscience-us-two-centers-of-excellence.-one-connected-research-network